PMID- 1386872
OWN - NLM
STAT- MEDLINE
DCOM- 19920916
LR  - 20190508
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 176
IP  - 2
DP  - 1992 Aug 1
TI  - Demonstration of a second ligand for the low affinity receptor for immunoglobulin 
      E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes.
PG  - 389-97
AB  - Recombinant full-length human CD23 has been incorporated into fluorescent 
      liposomes to demonstrate the existence of a ligand for CD23 that is different 
      from the previously known ligand, immunoglobulin E (IgE). The novel ligand for 
      CD23 is expressed on subsets of normal T cells and B cells as well as on some 
      myeloma cell lines. The interaction of full-length CD23 with its ligand is 
      specifically inhibited by anti-CD23 monoclonal antibodies and by IgE, and it is 
      Ca2+ dependent. Moreover, tunicamycin treatment of a CD23-binding cell line, RPMI 
      8226, significantly reduced the binding of CD23 incorporated into fluorescent 
      liposomes, and a sugar, fucose-1-phosphate, was found to inhibit CD23-liposome 
      binding to RPMI 8226 cells, suggesting the contribution of sugar structures on 
      the CD23 ligand. In addition, CD23-transfected COS cells were shown to form 
      specific conjugates with the cell line RPMI 8226. These data demonstrate that 
      CD23 interacts with a ligand, which is different from IgE, and that CD23 can be 
      considered as a new surface adhesion molecule involved in cell-cell interactions.
FAU - Pochon, S
AU  - Pochon S
AD  - Glaxo Institute for Molecular Biology, Plan-Les-Ouates, Geneva, Switzerland.
FAU - Graber, P
AU  - Graber P
FAU - Yeager, M
AU  - Yeager M
FAU - Jansen, K
AU  - Jansen K
FAU - Bernard, A R
AU  - Bernard AR
FAU - Aubry, J P
AU  - Aubry JP
FAU - Bonnefoy, J Y
AU  - Bonnefoy JY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Ligands)
RN  - 0 (Liposomes)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, IgE)
RN  - 0 (Recombinant Proteins)
RN  - 11089-65-9 (Tunicamycin)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antibody Specificity
MH  - Antigens, CD/immunology/*metabolism
MH  - Antigens, Differentiation, B-Lymphocyte/immunology/*metabolism
MH  - Blotting, Western
MH  - Calcium/metabolism
MH  - Cell Line
MH  - Flow Cytometry
MH  - Fluorescent Dyes
MH  - Humans
MH  - Immunoglobulin E/immunology/*metabolism
MH  - Ligands
MH  - Liposomes/immunology/*metabolism
MH  - Lymphocyte Subsets/metabolism
MH  - Receptors, Fc/immunology/*metabolism
MH  - Receptors, IgE
MH  - Recombinant Proteins/immunology/metabolism
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Tunicamycin/pharmacology
PMC - PMC2119325
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
PMCR- 1993/02/01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
PHST- 1993/02/01 00:00 [pmc-release]
AID - 92364541 [pii]
AID - 10.1084/jem.176.2.389 [doi]
PST - ppublish
SO  - J Exp Med. 1992 Aug 1;176(2):389-97. doi: 10.1084/jem.176.2.389.